{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:13:05Z","timestamp":1788833585673,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00520-020-05556-0","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T08:02:42Z","timestamp":1592035362000},"page":"925-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-3137","authenticated-orcid":false,"given":"Terry L.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed F. K.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Basulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon F.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirrtha","family":"Srikanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Stober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sienkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahwon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif A.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,13]]},"reference":[{"key":"5556_CR1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588\u20131594","journal-title":"Cancer"},{"key":"5556_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","volume":"18","author":"RK Hernandez","year":"2018","unstructured":"Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH (2018) Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer 18:44. https:\/\/doi.org\/10.1186\/s12885-017-3922-0","journal-title":"BMC Cancer"},{"key":"5556_CR3","doi-asserted-by":"publisher","first-page":"e16074","DOI":"10.1200\/jco.2013.31.15_suppl.e16074","volume":"31","author":"P Moretto","year":"2013","unstructured":"Moretto P, Hutton B, Kuchuk I, Canil CM, Ng TL, Addison CL, Clemons MJ (2013) Skeletal-related events (SRE) and bone-targeted agents for metastatic prostate cancer: are we changing outcomes? JCO 31:e16074\u2013e16074. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.e16074","journal-title":"JCO"},{"key":"5556_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","volume":"2","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M (2013) Incidence, consequences and treatment of bone metastases in breast cancer patients\u2014experience from a single cancer centre. J Bone Oncol 2:137\u2013144. https:\/\/doi.org\/10.1016\/j.jbo.2013.09.001","journal-title":"J Bone Oncol"},{"key":"5556_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3747\/co.19.1011","volume":"19","author":"M Clemons","year":"2012","unstructured":"Clemons M, Gelmon KA, Pritchard KI, Paterson AHG (2012) Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 19:259\u2013268. https:\/\/doi.org\/10.3747\/co.19.1011","journal-title":"Curr Oncol"},{"key":"5556_CR6","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2174\/138161210791034003","volume":"16","author":"I Holen","year":"2010","unstructured":"Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16:1262\u20131271","journal-title":"Curr Pharm Des"},{"key":"5556_CR7","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377\u2013387","journal-title":"Cancer J"},{"key":"5556_CR8","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","volume":"35","author":"C Van Poznak","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Barlow WE et al (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol 35:3978\u20133986. https:\/\/doi.org\/10.1200\/JCO.2017.75.4614","journal-title":"J Clin Oncol"},{"key":"5556_CR9","unstructured":"Gradishar WJ, Anderson BO, Abraham J (2019) NCCN breast cancer guidelines. Breast Cancer 217"},{"key":"5556_CR10","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ, Kennedy I, Allan SG, Mellars K (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785\u20131791. https:\/\/doi.org\/10.1056\/NEJM199612123352401","journal-title":"N Engl J Med"},{"key":"5556_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"5556_CR12","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002","journal-title":"Eur J Cancer"},{"key":"5556_CR13","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139. https:\/\/doi.org\/10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"key":"5556_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O\u2019Connor T, Velasco MR Jr, Weckstein D, O\u2019Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48\u201358. https:\/\/doi.org\/10.1001\/jama.2016.19425","journal-title":"JAMA"},{"key":"5556_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"GN Hortobagyi","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG et al (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 3:906\u2013912. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6316","journal-title":"JAMA Oncol"},{"key":"5556_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","volume":"10","author":"V Guarneri","year":"2005","unstructured":"Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF (2005) Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 10:842\u2013848. https:\/\/doi.org\/10.1634\/theoncologist.10-10-842","journal-title":"Oncologist"},{"key":"5556_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1185\/03007995.2012.689254","volume":"28","author":"H Henk","year":"2012","unstructured":"Henk H, Teitelbaum A, Kaura S (2012) Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid. Curr Med Res Opin 28:1119\u20131127. https:\/\/doi.org\/10.1185\/03007995.2012.689254","journal-title":"Curr Med Res Opin"},{"key":"5556_CR18","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andr\u00e9 F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:1926\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1810527","journal-title":"N Engl J Med"},{"key":"5556_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307\u2013316. https:\/\/doi.org\/10.1056\/NEJMoa1903765","journal-title":"N Engl J Med"},{"key":"5556_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B (2017) Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol 71:151\u2013154. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.032","journal-title":"Eur Urol"},{"key":"5556_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, de Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152\u2013160. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7","journal-title":"Lancet Oncol"},{"key":"5556_CR22","first-page":"CRD42019126813","volume":"2019","author":"T Ng","year":"2019","unstructured":"Ng T, Awan AA, Clemons MJ et al (2019) Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases. PROSPERO 2019:CRD42019126813","journal-title":"PROSPERO"},{"key":"5556_CR23","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"5556_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"5556_CR25","unstructured":"Wells G, Shea B, O\u2019Connell D, et al (2009) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses"},{"key":"5556_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"key":"5556_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body J-J, Brown JE, Carducci M, Diel I, Fujiwara Y, Mart\u00edn M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447\u2013455. https:\/\/doi.org\/10.1007\/s00520-015-2904-5","journal-title":"Support Care Cancer"},{"key":"5556_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","volume":"26","author":"M Pecherstorfer","year":"2006","unstructured":"Pecherstorfer M, Rivkin S, Body J-J, Diel I, Bergstr\u00f6m B (2006) Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 26:315\u2013322. https:\/\/doi.org\/10.2165\/00044011-200626060-00002","journal-title":"Clin Drug Investig"},{"key":"5556_CR29","doi-asserted-by":"publisher","unstructured":"Bal O, Oksuzoglu B, Dogan M, Durnali A, Uyeturk U, Demirci A, Arslan UY, Ekinci AS, Yildirim N, Alkis N, Kilic S (2019) Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-019-02120-6","DOI":"10.1007\/s11845-019-02120-6"},{"key":"5556_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.breast.2012.04.008","volume":"21","author":"X Ding","year":"2012","unstructured":"Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B (2012) Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast 21:544\u2013549. https:\/\/doi.org\/10.1016\/j.breast.2012.04.008","journal-title":"Breast"},{"key":"5556_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12032-008-9045-3","volume":"25","author":"M Dincer","year":"2008","unstructured":"Dincer M, Altundag K, Harputluoglu H, Aksoy S, Cengiz M, Gullu I (2008) Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol 25:356\u2013359. https:\/\/doi.org\/10.1007\/s12032-008-9045-3","journal-title":"Med Oncol"},{"key":"5556_CR32","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580\u20138587. https:\/\/doi.org\/10.1200\/JCO.2005.02.8670","journal-title":"J Clin Oncol"},{"key":"5556_CR33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.22504","volume":"109","author":"WK Oh","year":"2007","unstructured":"Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antr\u00e0s L, Smith M, Neary MP, Duh MS (2007) The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 109:1090\u20131096. https:\/\/doi.org\/10.1002\/cncr.22504","journal-title":"Cancer"},{"key":"5556_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/annonc\/mdl408","volume":"18","author":"D Aguiar Bujanda","year":"2007","unstructured":"Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Su\u00e1rez MA, Aguiar Morales J (2007) Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18:556\u2013560. https:\/\/doi.org\/10.1093\/annonc\/mdl408","journal-title":"Ann Oncol"},{"key":"5556_CR35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/tbj.12152","volume":"19","author":"AM Brufsky","year":"2013","unstructured":"Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M (2013) Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J 19:504\u2013511. https:\/\/doi.org\/10.1111\/tbj.12152","journal-title":"Breast J"},{"key":"5556_CR36","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jos.2017.04.011","volume":"22","author":"E Nakata","year":"2017","unstructured":"Nakata E, Sugihara S, Yamashita N, Osumi S (2017) The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment. J Orthop Sci 22:946\u2013950. https:\/\/doi.org\/10.1016\/j.jos.2017.04.011","journal-title":"J Orthop Sci"},{"key":"5556_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663\u2013670. https:\/\/doi.org\/10.1016\/S1470-2045(13)70174-8","journal-title":"Lancet Oncol"},{"key":"5556_CR38","doi-asserted-by":"publisher","first-page":"11501","DOI":"10.1200\/JCO.2019.37.15_suppl.11501","volume":"37","author":"MJ Clemons","year":"2019","unstructured":"Clemons MJ, Ong M, Stober C et al (2019) A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. JCO 37:11501\u201311501. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.11501","journal-title":"JCO"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05556-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05556-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05556-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T23:32:19Z","timestamp":1623540739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05556-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,13]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5556"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05556-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,13]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}